TY - JOUR
T1 - Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer
AU - Giambona, Antonino
AU - Gioco, Pina Lo
AU - Marino, Marisa
AU - Abate, Ida
AU - Di Marzo, Rosalba
AU - Renda, Mariella
AU - Di Trapani, Francesca
AU - Messana, Francesca
AU - Siciliano, Salvo
AU - Rigano, Paolo
AU - Chehab, Farid F.
AU - Kazazian, Haig H.
AU - Maggio, Aurelio
PY - 1995/5
Y1 - 1995/5
N2 - This paper reports the results of 1428 β-thalassemia chromosomes studied in Sicily during a hemoglobinopathy control program starting in 1983. Molecular screening was performed by direct restriction enzyme analysis, allele specific oligonucleotide (ASO) hybridization, reverse dot blot analysis (RDB) and, for the rare or new mutations, by direct sequencing of polymerase chain reaction (PCR) products. Using these approaches 1410 (98.7%) out of 1428 β-globin gene defects were characterized, involving 22 different β-thalassemia mutations. Three of these were present at high frequency (β{ring operator}39, IVS1, 110 and IVS1,6); the other β-globin gene defects were found at low frequency. In the latter, we found a smaller group of mutations at a frequency lower than 10% (IVS1, 1, IVS2, 745, β S) and a larger one at a frequency lower than 2% [-87, IVS1,2, IVS2,1, fr 6, fr 8 (-AA), fr 44, fr 76, -101, IVS1, 116, IVS1, 3′end G-C, IVS1,5 G-A, IVS1,5 G-C, cod 30, Lepore, deltaβ, β C]. The possible origin of this very large number of mutations is discussed, taking into account the historical point of view. Moreover, this approach has made a first trimester prenatal diagnosis program possible in our region in practically all cases, with a great improvement in general thalassemia management.
AB - This paper reports the results of 1428 β-thalassemia chromosomes studied in Sicily during a hemoglobinopathy control program starting in 1983. Molecular screening was performed by direct restriction enzyme analysis, allele specific oligonucleotide (ASO) hybridization, reverse dot blot analysis (RDB) and, for the rare or new mutations, by direct sequencing of polymerase chain reaction (PCR) products. Using these approaches 1410 (98.7%) out of 1428 β-globin gene defects were characterized, involving 22 different β-thalassemia mutations. Three of these were present at high frequency (β{ring operator}39, IVS1, 110 and IVS1,6); the other β-globin gene defects were found at low frequency. In the latter, we found a smaller group of mutations at a frequency lower than 10% (IVS1, 1, IVS2, 745, β S) and a larger one at a frequency lower than 2% [-87, IVS1,2, IVS2,1, fr 6, fr 8 (-AA), fr 44, fr 76, -101, IVS1, 116, IVS1, 3′end G-C, IVS1,5 G-A, IVS1,5 G-C, cod 30, Lepore, deltaβ, β C]. The possible origin of this very large number of mutations is discussed, taking into account the historical point of view. Moreover, this approach has made a first trimester prenatal diagnosis program possible in our region in practically all cases, with a great improvement in general thalassemia management.
UR - http://www.scopus.com/inward/record.url?scp=34249757297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249757297&partnerID=8YFLogxK
U2 - 10.1007/BF00223864
DO - 10.1007/BF00223864
M3 - Article
AN - SCOPUS:34249757297
SN - 0340-6717
VL - 95
SP - 526
EP - 530
JO - Human genetics
JF - Human genetics
IS - 5
ER -